Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy

References

• McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis 2010;14:461–76
   PubMed Web of Science ®Google Scholar
• Juday T, Tang H, Harris M, et al. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med 2011;26:239–44
   PubMedGoogle Scholar
• Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008;14:6902–10
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–85
   PubMed Web of Science ®Google Scholar
• Nettleman M. Hepatitis B. emedicine health. http://www.emedicinehealth.com/hepatitis_b/article_em.htm. Accessed December 13, 2011.
   Google Scholar
• Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61:362–66
   PubMed Web of Science ®Google Scholar
• Lee H, Park W, Yang JH, et al. Management of hepatitis B virus infection. Gastroenterol Nurs 2010;33:120–6
   PubMedGoogle Scholar
• World Health Organization. Global alert and response: hepatitis B. 2012. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index3.html. Accessed May 29, 2012
   Google Scholar
• Papatheodoridis GV. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver Int 2011;31:748
   Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–2
   PubMed Web of Science ®Google Scholar
• Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother 2011;12:2025–40
   PubMed Web of Science ®Google Scholar
• Fuentes Olmo J, Uribarrena Amezaga R. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?]. Gastroentrol Hepatol 2011;34:492–503
   PubMedGoogle Scholar
• Colonno R, Rose R, Baldick C, et al. Resistance after two years of entecavir treatment in nucleoside-naïve patients is rare. Hepatology 2006;45:1656–65
   Google Scholar
• Ristig MB, Crippin J, Abert JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844–7
   PubMed Web of Science ®Google Scholar
• Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleoside binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449–55
   PubMed Web of Science ®Google Scholar
• Health Insurance Portability and Accountability Act of 1996. Public law 104-191, 104th Congress, U.S. Department of Health and Human Services. 1996. http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Accessed December 13, 2011
   Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Washington, DC: US Department of Labor 2011.
   Google Scholar
• Shamiliyan TA, Johnson JR, MacDonald R, et al. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326–39
   PubMedGoogle Scholar
• Fung J, Lai CL, Yuen J, et al. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 years. Hepatology 2011;53:1148–53
   PubMedGoogle Scholar
• Lam YF, Yuen MF, Seto WK, et al. Current antiviral therapy of chronic hepatitis B: efficacy and safety. Curr Hepat Rep 2011;10:235–43
   PubMedGoogle Scholar
• Yoon EL, Yim HJ, Lee YS, et al. Comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B virus infection: two-year follow-up data. J Clin Gastroenterol 2011;45:893–9
   PubMedGoogle Scholar
• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91–100
   PubMed Web of Science ®Google Scholar
• Zhao SS, Tang LH, Dai XH, et al. Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. Virol J 2011;8:111
   PubMedGoogle Scholar
• Almeida AM, da Silva AL, Cherchiglia ML, et al. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine. Value Health 2011;14(5 Suppl 1):S24–8
   PubMedGoogle Scholar
• Wiens A, Venson R, Correr CJ, et al. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. Braz J Infect Dis 2011;15:225–30
   PubMedGoogle Scholar
• Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008;26:937–49
   PubMedGoogle Scholar
• Arnold E, Yuan Y, Iloeje U, et al. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy 2008;6:231–46
   PubMedGoogle Scholar
• Chen W, Hou JL. [Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B.] Zhonghua Gan Zang Bing Za Zhi 2009;17:569–73
   PubMedGoogle Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001–10
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011–20
   PubMed Web of Science ®Google Scholar
• Lam YF, Yuen MF, Seto WK, et al. Current antiviral therapy of chronic hepatitis B: efficacy and safety. Curr Hepat Rep 2011;10:235–43
   PubMedGoogle Scholar
• Papatheodoridis GV. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver Int 2011;31(1 Suppl):95–103
   PubMedGoogle Scholar
• Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012;56(Suppl):S112–22
   Google Scholar
• Leung N. Treatment of HbeAg-positive chronic hepatitis B with nucleos(t)ide analogues. Liver Int 2011;31(1 Suppl):85–9
   PubMedGoogle Scholar
• Hiotis SP, Rahbari NN, Villanueva GA, et al. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol 2012;12:64
   Google Scholar
• Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroenterol Hepatol 2011;26:221–7
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005;43:1130–9
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373–83
   PubMedGoogle Scholar